|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0023434,
umls-concept:C0036667,
umls-concept:C0312418,
umls-concept:C0441655,
umls-concept:C0449438,
umls-concept:C0663914,
umls-concept:C0681842,
umls-concept:C1171350,
umls-concept:C1174144,
umls-concept:C1420556,
umls-concept:C1421567,
umls-concept:C1424530,
umls-concept:C1527940,
umls-concept:C1705831
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-4-16
|
|
pubmed:abstractText |
Constitutive nuclear factor-kappaB (NF-kappaB) activation has been implicated in the pathogenesis of chronic lymphocytic leukemia (CLL). Our purpose was to characterize the molecular mechanisms underlying for the selective IkappaB kinase inhibitor BMS-345541 in CLL cells together with the analysis of its combination with several antineoplasic drugs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2767-76
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19351760-Adult,
pubmed-meshheading:19351760-Aged,
pubmed-meshheading:19351760-Aged, 80 and over,
pubmed-meshheading:19351760-Apoptosis,
pubmed-meshheading:19351760-Drug Resistance, Neoplasm,
pubmed-meshheading:19351760-Drug Synergism,
pubmed-meshheading:19351760-Female,
pubmed-meshheading:19351760-Humans,
pubmed-meshheading:19351760-I-kappa B Kinase,
pubmed-meshheading:19351760-Imidazoles,
pubmed-meshheading:19351760-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:19351760-Male,
pubmed-meshheading:19351760-Middle Aged,
pubmed-meshheading:19351760-NF-kappa B,
pubmed-meshheading:19351760-Quinoxalines,
pubmed-meshheading:19351760-Transcription Factor RelA,
pubmed-meshheading:19351760-ZAP-70 Protein-Tyrosine Kinase
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
|
|
pubmed:affiliation |
Authors' Affiliations: Hematopathology Unit, Department of Pathology and Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
